Breaking News Instant updates and real-time market news.

REGN

Regeneron

$312.77

-11.38 (-3.51%)

, NVS

Novartis

$81.86

0.82 (1.01%)

07:32
05/13/19
05/13
07:32
05/13/19
07:32

Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald

Cantor Fitzgerald analyst Regeneron Pharmaceuticals (REGN) to $405 from $441 saying the company's expenses are tracking higher than his projections. Further, he thinks investor concerns about Novartis' (NVS) brolucizumab approval in eye and increased atopic dermatitis competition remain headwinds for share upside. The analyst reiterates a Neutral rating on Regeneron following its Q1 results.

REGN

Regeneron

$312.77

-11.38 (-3.51%)

NVS

Novartis

$81.86

0.82 (1.01%)

  • 13

    May

  • 14

    May

  • 23

    May

  • 31

    May

  • 26

    Jun

REGN Regeneron
$312.77

-11.38 (-3.51%)

05/07/19
PIPR
05/07/19
NO CHANGE
Target $435
PIPR
Overweight
Regeneron price target lowered to $435 from $487 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond lowered his price target on Regeneron to $435 after its below-consensus Q1 earnings and the first revenue miss since Q4 of 2016, driven by weakness in Praluent sales and higher than expected operating expenditures. The analyst adds that the two deaths disclosed with the company's REGN1979 phase 1 study "didn't help things." Raymond maintains his Overweight rating on Regeneron however, anticipating Eylea and Dupixent to continue to "grow ahead of expectations."
05/08/19
UBSW
05/08/19
NO CHANGE
Target $440
UBSW
Buy
Regeneron price target lowered to $440 from $480 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron to $440 after its Q1 results, saying the quarter's "decent" Eylea print and continued Dupixent growth were overshadowed by higher than expected operating expense and two reported deaths in its an early-stage lymphoma study. The analyst keeps his Buy rating on the stock, noting that the concerns over the R&D expense are likely "overdone", even though he expects the FY19 consensus to reset lower after this quarter. Gould adds that Regeneron's REGN1979 data at June's EHA is an "important catalyst" for the stock.
05/08/19
ADAM
05/08/19
NO CHANGE
Target $353
ADAM
Hold
Regeneron price target cut to $353 from $408 at Canaccord
Canaccord analyst John Newman cut his price target for Regeneron to $353 from $408 and maintained a Hold rating following the company's Q1 results, saying R&D expense and 2019 guidance surprised investors, although he thinks more R&D investment is beneficial in the long-term, despite short-term pains. However, the increase in R&D spending may persist due to ongoing early pipeline programs, Libtayo development costs, higher clinical manufacturing costs, and higher headcount, Newman tells investors in a research note.
05/08/19
BMOC
05/08/19
NO CHANGE
Target $375
BMOC
Market Perform
Regeneron price target lowered to $375 from $412 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron (REGN) to $375 after its "uninspiring" Q1 driven by higher R&D costs and lower collaboration revenue with Sanofi (SNY). The analyst notes that while the company's Dupixent is "showing progress" and Eylea's 8% revenue growth is a positive, he is also concerned with higher discounting for the latter along with the potential for a more competitive vascular endothelial growth factor, or VEGF, landscape. Luchini keeps his Market Perform rating on Regeneron.
NVS Novartis
$81.86

0.82 (1.01%)

05/02/19
FBCO
05/02/19
INITIATION
Target $66
FBCO
Outperform
Alcon initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic started coverage of Alcon (ALC) with an Outperform rating and a $66 price target. Recently spun off from parent Novartis (NVS), Alcon is now positioned to deliver improving growth and margins, the analyst contends. Miksic believes the key to the Alcon investment case is the opportunity to increase revenue growth and margins through expanded market share and its leadership positions in cataract, retinal surgery, contact lenses and consumer eye care.
05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.

TODAY'S FREE FLY STORIES

MO

Altria Group

$46.57

0.32 (0.69%)

05:57
08/23/19
08/23
05:57
08/23/19
05:57
Upgrade
Altria Group rating change  »

Altria Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,804.00

-19.19 (-1.05%)

05:52
08/23/19
08/23
05:52
08/23/19
05:52
Periodicals
Amazon to stop using tips to cover wages for Flex drivers, LA Times reports »

Amazon says it will no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

OXY

Occidental Petroleum

$44.69

-0.35 (-0.78%)

05:49
08/23/19
08/23
05:49
08/23/19
05:49
Initiation
Occidental Petroleum initiated  »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

LZB

La-Z-Boy

$31.52

1.48 (4.93%)

05:45
08/23/19
08/23
05:45
08/23/19
05:45
Upgrade
La-Z-Boy rating change  »

La-Z-Boy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

05:45
08/23/19
08/23
05:45
08/23/19
05:45
Downgrade
HP Inc. rating change  »

HP Inc. downgraded In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HCM

Hutchison China MediTech

$20.53

0.13 (0.64%)

05:34
08/23/19
08/23
05:34
08/23/19
05:34
Hot Stocks
Chi-Med initiates Phase I study of HMPL-523 »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

SMSEY

Samsonite International

$0.00

(0.00%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Samsonite International management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

URBN

Urban Outfitters

$23.91

1.53 (6.84%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Urban Outfitters management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Nov

SERV

ServiceMaster

$58.21

0.37 (0.64%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
ServiceMaster management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

04:55
08/23/19
08/23
04:55
08/23/19
04:55
General news
Breaking General news story  »

Federal Reserve Chairman…

GLOB

Globant

$96.92

3.21 (3.43%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Globant management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

04:55
08/23/19
08/23
04:55
08/23/19
04:55
General news
New Home Sales to be reported at 10:00 »

July New Home Sales will…

GKOS

Glaukos

$61.31

-1.71 (-2.71%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Glaukos management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 26

    Aug

  • 04

    Sep

  • 13

    Nov

AMAT

Applied Materials

$47.04

0.21 (0.45%)

, AMD

AMD

$31.90

0.2 (0.63%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
MUFG Securities to hold a tour »

MUFG Securities Tech Tour…

AMAT

Applied Materials

$47.04

0.21 (0.45%)

AMD

AMD

$31.90

0.2 (0.63%)

ANET

Arista Networks

$227.19

0.48 (0.21%)

CHKP

Check Point

$109.20

-0.01 (-0.01%)

CSCO

Cisco

$48.20

-0.59 (-1.21%)

EQIX

Equinix

$554.08

2.15 (0.39%)

FLEX

Flex

$10.26

0.26 (2.60%)

INTC

Intel

$46.76

-0.39 (-0.83%)

NVDA

Nvidia

$171.44

0.21 (0.12%)

OTEX

OpenText

$39.11

0.18 (0.46%)

PYPL

PayPal

$108.74

-1.09 (-0.99%)

RNG

RingCentral

$142.36

2.33 (1.66%)

SQ

Square

$64.65

-0.78 (-1.19%)

STX

Seagate

$47.58

0.36 (0.76%)

TWLO

Twilio

$130.48

-0.57 (-0.43%)

V

Visa

$180.15

-0.8 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Wolfe Research healthcare analysts to hold an analyst/industry webcast »

Global Pharma Analyst…

04:55
08/23/19
08/23
04:55
08/23/19
04:55
General news
Breaking General news story  »

Week of 8/23 Baker-Hughes…

CMS

CMS Energy

$62.13

0.04 (0.06%)

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
CMS Energy management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 10

    Nov

04:55
08/23/19
08/23
04:55
08/23/19
04:55
Conference/Events
Cowen retail analysts to hold an analyst/industry conference call »

Retail Analyst Chen,…

03:50
08/23/19
08/23
03:50
08/23/19
03:50
General news
FX Action: USD-CAD nudged out a three-day high »

FX Action: USD-CAD nudged…

03:05
08/23/19
08/23
03:05
08/23/19
03:05
General news
FX Update: The New Zealand dollar outperformed and China's yuan weakened »

FX Update: The New…

LLY

Eli Lilly

$111.63

0.2 (0.18%)

21:03
08/22/19
08/22
21:03
08/22/19
21:03
Hot Stocks
Arbitration panel rules in favor of Eli Lilly in Adocia IP claim »

A Chicago-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

FL

Foot Locker

$42.00

2.24 (5.63%)

, HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

20:25
08/22/19
08/22
20:25
08/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$42.00

2.24 (5.63%)

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

, AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

19:40
08/22/19
08/22
19:40
08/22/19
19:40
Hot Stocks
Trump 'hopeful' to work with Congress on' legislation addressing mass shootings »

President Donald Trump…

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

VSTO

Vista Outdoor

$5.33

0.26 (5.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 10

    Sep

  • 19

    Sep

TOT

Total

$48.98

-0.18 (-0.37%)

19:16
08/22/19
08/22
19:16
08/22/19
19:16
Downgrade
Total rating change at Citi »

Total downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPR

Kemper

$75.42

0.48 (0.64%)

19:14
08/22/19
08/22
19:14
08/22/19
19:14
Downgrade
Kemper rating change at William Blair »

Kemper downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 11

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.